# OnCo record mycosis-fungoides (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mycosis-fungoides/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mycosis-fungoides" ;
  schema:name "Mycosis fungoides"@en ;
  schema:alternateName "MF"@en, "Mycosis fungoides / Sezary syndrome (CTCL)"@en, "Alibert-Bazin syndrome"@en, "Granuloma fungoides"@en, "Folliculotropic mycosis fungoides"@en, "Pagetoid reticulosis"@en, "Granulomatous slack skin"@en ;
  schema:description "The commonest cutaneous T-cell lymphoma, and a disease that behaves like a long-term skin condition for most of the people who have it: flat scaly patches that have often been treated as eczema or psoriasis for years before anyone takes a biopsy. In its early stages life expectancy is close to normal, and the treatment is creams and light rather than chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/mycosis-fungoides/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mycosis_fungoides> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1200/JCO.2009.27.7665>, <https://doi.org/10.1016/j.clml.2015.02.027>, <https://doi.org/10.1038/bjc.2015.94>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/lymphomatoid-papulosis/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/total-skin-electron-therapy/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/vorinostat/>, <https://onco.cc/drugs/denileukin-diftitox/>, <https://onco.cc/drugs/methoxsalen-ecp/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-nodal-versus-extranodal/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-transformation/>, <https://onco.cc/terms/lymphoma-tx-uk-access/> ;
  onco:trials <https://onco.cc/trials/alcanza/>, <https://onco.cc/trials/mavoric/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/> ;
  onco:standardOfCare <https://onco.cc/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/imiquimod/>, <https://onco.cc/technologies/total-skin-electron-therapy/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/key-papers/paper-study-201-jama-dermatol-2013/>, <https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/bexarotene/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/vorinostat/>, <https://onco.cc/drugs/denileukin-diftitox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/bexarotene/> .